- Dry Eye Syndrome (DES) is a multifactorial ocular surface disease characterized by loss of tear film homeostasis. Common symptoms include irritation, blurred vision, and discomfort. The Asia-Pacific region has experienced a surge in DES cases due to rising screen time, urban pollution, and hormonal changes.
- Non-invasive diagnostic technologies, increasing patient education campaigns, and widespread OTC availability of lubricating drops are enhancing early diagnosis and treatment rates. Major advances in lipid-based formulations and inflammation-targeted drugs are expected to reshape the treatment landscape.
- India and China are projected to lead market share owing to large population base, increasing healthcare expenditure, and robust local manufacturing of generics and ophthalmic solutions.
- Japan and South Korea are experiencing a rise in DES prevalence among aging and tech-savvy demographic
- In 2025, the Artificial Tears segment is expected to hold the largest share of 49.8%, due to their ease of availability, affordability, and established use in first-line therapy.
